Ubs Oconnor LLC Spring Works Therapeutics, Inc. Transaction History

Ubs Oconnor LLC

$1.46 Billion
Q3 2024

A detailed history of Ubs Oconnor LLC transactions in Spring Works Therapeutics, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 28,513 shares of SWTX stock, worth $1.07 Million. This represents 0.06% of its overall portfolio holdings.

Number of Shares

28,513

Holding current value

$1.07 Million

% of portfolio

0.06%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$32.04 - $42.76 $118,580 - $158,254	-3,701 Reduced 11.49%	28,513 $913,000
Q2 2024 Aug 14, 2024	SELL	$36.06 - $47.62 $542,198 - $716,014	-15,036 Reduced 31.82%	32,214 $1.21 Million
Q1 2024 May 15, 2024	SELL	$36.5 - $52.5 $1.02 Million - $1.47 Million	-28,000 Reduced 37.21%	47,250 $2.33 Million
Q4 2023 Feb 14, 2024	SELL	$18.94 - $37.24 $340,654 - $669,798	-17,986 Reduced 19.29%	75,250 $2.75 Million
Q3 2023 Nov 14, 2023	SELL	$23.12 - $31.38 $517,818 - $702,817	-22,397 Reduced 19.37%	93,236 $2.16 Million
Q2 2023 Aug 14, 2023	BUY	$23.15 - $32.71 $2.68 Million - $3.78 Million	115,633 New	115,633 $3.03 Billion
Q1 2023 May 15, 2023	SELL	$24.97 - $34.05 $300,513 - $409,791	-12,035 Reduced 10.78%	99,580 $2.56 Million
Q4 2022 Feb 14, 2023	BUY	$21.73 - $28.72 $469,846 - $620,983	21,622 Added 24.03%	111,615 $0
Q3 2022 Nov 14, 2022	BUY	$24.1 - $39.66 $204,850 - $337,110	8,500 Added 10.43%	89,993 $2.57 Billion
Q2 2022 Aug 12, 2022	BUY	$18.36 - $60.07 $1.1 Million - $3.6 Million	59,893 Added 277.28%	81,493 $2.01 Million
Q1 2022 May 16, 2022	BUY	$48.97 - $65.46 $1.06 Million - $1.41 Million	21,600 New	21,600 $1.22 Million

Others Institutions Holding SWTX

# of Institutions

238

Shares Held

69.8M

Call Options Held

144K

Put Options Held

257K

View Full List

About SpringWorks Therapeutics, Inc.

Ticker SWTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,401,100
Market Cap $2.34B
Description
SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also deve...

More about SWTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.

Account